CN112702993A - 适用于关节递送的药物组合物及其在治疗关节疼痛中的用途 - Google Patents

适用于关节递送的药物组合物及其在治疗关节疼痛中的用途 Download PDF

Info

Publication number
CN112702993A
CN112702993A CN201980059773.8A CN201980059773A CN112702993A CN 112702993 A CN112702993 A CN 112702993A CN 201980059773 A CN201980059773 A CN 201980059773A CN 112702993 A CN112702993 A CN 112702993A
Authority
CN
China
Prior art keywords
pharmaceutical composition
μmol
phospholipids
amount
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980059773.8A
Other languages
English (en)
Chinese (zh)
Inventor
曾云龙
施雪芳
张博钧
张珞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiwan Liposome Co Ltd
TLC Biopharmaceuticals Inc
Original Assignee
Taiwan Liposome Co Ltd
TLC Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Co Ltd, TLC Biopharmaceuticals Inc filed Critical Taiwan Liposome Co Ltd
Publication of CN112702993A publication Critical patent/CN112702993A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980059773.8A 2018-09-16 2019-09-16 适用于关节递送的药物组合物及其在治疗关节疼痛中的用途 Pending CN112702993A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862731941P 2018-09-16 2018-09-16
US62/731,941 2018-09-16
PCT/US2019/051247 WO2020056399A1 (en) 2018-09-16 2019-09-16 Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain

Publications (1)

Publication Number Publication Date
CN112702993A true CN112702993A (zh) 2021-04-23

Family

ID=68084954

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980059773.8A Pending CN112702993A (zh) 2018-09-16 2019-09-16 适用于关节递送的药物组合物及其在治疗关节疼痛中的用途

Country Status (15)

Country Link
US (1) US12208104B2 (https=)
EP (1) EP3849522A1 (https=)
JP (1) JP7634476B2 (https=)
KR (1) KR20210060559A (https=)
CN (1) CN112702993A (https=)
AU (1) AU2019339528B2 (https=)
BR (1) BR112021004880A2 (https=)
CA (1) CA3112234A1 (https=)
CL (1) CL2021000627A1 (https=)
IL (1) IL281513A (https=)
MX (1) MX2021003030A (https=)
SG (1) SG11202102400PA (https=)
TW (1) TWI843751B (https=)
WO (1) WO2020056399A1 (https=)
ZA (1) ZA202101688B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3187955A1 (en) 2020-08-05 2022-02-10 Sheue-Fang Shih Pharmaceutical composition of intra-articular corticosteroid for pain control
WO2024230404A1 (zh) * 2023-05-05 2024-11-14 中南大学湘雅医院 一种治疗关节疼痛的氢氧化镁纳米粒、其制备方法及应用
TW202519194A (zh) * 2023-11-03 2025-05-16 台灣微脂體股份有限公司 用於疼痛控制之關節內皮質類固醇的微脂體組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152962A1 (en) * 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
CN105377238A (zh) * 2012-07-05 2016-03-02 台湾微脂体股份有限公司 治疗关节炎的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1371362A1 (en) * 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
DK2797601T3 (en) 2012-02-10 2018-06-14 Taiwan Liposome Co Ltd PHARMACEUTICAL COMPOSITIONS FOR REDUCING COMPLICATIONS BY Ocular steroid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152962A1 (en) * 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
CN105377238A (zh) * 2012-07-05 2016-03-02 台湾微脂体股份有限公司 治疗关节炎的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YIBO FENG ETAL.: "Optimization on Preparation Conditions of Salidroside Liposome and Its Immunological Activity on PCV-2 in Mice", 《EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE》 *

Also Published As

Publication number Publication date
TWI843751B (zh) 2024-06-01
JP7634476B2 (ja) 2025-02-21
US20210338688A1 (en) 2021-11-04
CL2021000627A1 (es) 2021-09-10
BR112021004880A2 (pt) 2021-06-01
IL281513A (en) 2021-04-29
SG11202102400PA (en) 2021-04-29
WO2020056399A1 (en) 2020-03-19
US12208104B2 (en) 2025-01-28
JP2022500364A (ja) 2022-01-04
TW202023569A (zh) 2020-07-01
ZA202101688B (en) 2024-06-26
MX2021003030A (es) 2021-05-27
AU2019339528A1 (en) 2021-04-15
AU2019339528B2 (en) 2025-01-30
CA3112234A1 (en) 2020-03-19
KR20210060559A (ko) 2021-05-26
EP3849522A1 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
JP6609286B2 (ja) ヒトにおける炎症性障害の治療用リポソームコルチコステロイド
AU2019339528B2 (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
EP3820479B1 (en) Methods to reduce complications of intra-articular steroid
HK40041739A (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
RU2810788C2 (ru) Фармацевтические композиции, подходящие для суставной доставки, и их применение при лечении суставной боли
RU2806023C2 (ru) Способы уменьшения осложнений от внутрисуставного стероида
US12514820B2 (en) Pharmaceutical composition of intra-articular corticosteroid for pain control
HK40087158A (zh) 用於疼痛控制的关节内皮质类固醇的药物组合物
HK40041258A (en) Methods to reduce complications of intra-articular steroid
WO2025096949A1 (en) Liposomal composition of intra-articular corticosteroid for pain control

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40041739

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination